Quorum Innovations LLC
Quorum Innovations is a biopharmaceutical company focused on discovering and developing human microbiome therapeutics. The company aims to become a leader in the emerging field of microbiome therapeutics, leveraging its proprietary drug discovery platform, MiNE™, to identify biotherapeutic candidates that stimulate the innate immune response and restore normal microbiome ecology.
Industries
Nr. of Employees
small (1-50)
Quorum Innovations LLC
2068 Hawthorne Street, Sarasota, FL 34239
Patents
Materials and methods for improving immune responses and skin and/or mucosal barrier functions
US-12440521-B2
View DetailsMaterials and methods for inhibiting a viral infection, including a coronavirus infection
US-11826390-B2
View DetailsMaterials and methods for improving immune responses and skin and/or mucosal barrier functions
US-11564957-B2
View Details
Materials and methods for improving immune responses and skin and/or mucosal barrier functions
US-12440521-B2
View DetailsMaterials and methods for inhibiting a viral infection, including a coronavirus infection
US-11826390-B2
View DetailsMaterials and methods for improving immune responses and skin and/or mucosal barrier functions
US-11564957-B2
View DetailsProducts
BioEsse (topical microbiome-derived skin product)
Commercial topical skin-health product line formulated with microbiome-derived bioactive extracts for skin applications.
Microbiome-derived therapeutic candidates (lead: atopic dermatitis)
Pipeline of microbiome-derived therapeutic candidates developed for local treatment of chronic inflammatory and barrier-deficiency conditions; lead program targets atopic dermatitis.
Intellectual property portfolio (issued US patents)
Issued US patents covering methods to identify biologically active compounds from microbial biofilm and compositions/methods for improving immune responses and barrier functions.
BioEsse (topical microbiome-derived skin product)
Commercial topical skin-health product line formulated with microbiome-derived bioactive extracts for skin applications.
Microbiome-derived therapeutic candidates (lead: atopic dermatitis)
Pipeline of microbiome-derived therapeutic candidates developed for local treatment of chronic inflammatory and barrier-deficiency conditions; lead program targets atopic dermatitis.
Intellectual property portfolio (issued US patents)
Issued US patents covering methods to identify biologically active compounds from microbial biofilm and compositions/methods for improving immune responses and barrier functions.
Services
Collaborative preclinical development, joint data generation and license/partnership discussions to advance microbiome-derived candidates toward clinical milestones.
Collaborative preclinical development, joint data generation and license/partnership discussions to advance microbiome-derived candidates toward clinical milestones.
Expertise Areas
- Microbiome-derived therapeutics
- Anti-biofilm therapeutics
- Translational medicine and early clinical development
- Topical formulation and local delivery
Key Technologies
- Biofilm-based compound discovery
- 96-well biofilm microplate assays
- Anti-adhesion and biofilm detachment assays
- Microbiome-derived bioactive extraction and processing
News & Updates
Dr. Nicholas Monsul will deliver a key address at the Annual Microbiome Summit in Vienna, Austria, discussing the capabilities to modulate the skin microbiota.
Quorum Innovations announced a major advancement in improving immune responses and skin/mucosal barrier by modulating the human microbiome.
Quorum Innovations is included in SVB Analytics - Emerging Healthcare: / 2017.
Quorum Innovations announced a major milestone that includes a drug discovery platform to advance the introduction of new treatments for skin, GI, inflammatory and metabolic conditions utilizing human microbiome therapeutics.
Quorum Innovations has successfully isolated LfQi6 from the human host, demonstrating strong biofilm formations and novel bimodal biofilm modulation.
Dr. Nicholas Monsul will deliver a key address at the Annual Microbiome Summit in Vienna, Austria, discussing the capabilities to modulate the skin microbiota.
Quorum Innovations announced a major advancement in improving immune responses and skin/mucosal barrier by modulating the human microbiome.
Quorum Innovations is included in SVB Analytics - Emerging Healthcare: / 2017.
Quorum Innovations announced a major milestone that includes a drug discovery platform to advance the introduction of new treatments for skin, GI, inflammatory and metabolic conditions utilizing human microbiome therapeutics.
Quorum Innovations has successfully isolated LfQi6 from the human host, demonstrating strong biofilm formations and novel bimodal biofilm modulation.